Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
about
Chemotherapy versus best supportive care for extensive small cell lung cancerTargeted drugs in small-cell lung cancerTreatment for small cell lung cancer, where are we now?-a reviewTargeting angiogenesis in small cell lung cancerAmrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patientsNew and emerging developments in extensive-stage small cell lung cancer therapeuticsCheckpoint inhibitors in lung cancer: latest developments and clinical potentialThe Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung CancerVAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II studyPhase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancerSystematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPhase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerRetrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochlorideA phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasTrial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Lung cancer: current diagnosis and treatmentTreatment options for small cell lung cancer - do we have more choice?Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature.Neuroendocrine carcinoma of the cervix presenting as intractable hyponatremic seizures due to paraneoplastic SIADH-a rare case report and brief review of the literatureSouthwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Small cell lung cancer: therapies and targetsA systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancerThe role of anthracyclines in small cell lung cancer.Topotecan in the treatment of relapsed small cell lung cancer.Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerCurrent and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
P2860
Q24240652-F341466E-6498-4EC3-850B-35C7BD6E5169Q26767017-5882B125-B897-483C-B43D-9A8FA596954CQ26767023-20A2E165-7762-4A93-97AC-132DC491A7CDQ28068385-EFD59D7C-C5FB-463F-9B89-7E0D4A7BAF24Q28072672-21CA1E4B-19C9-45FA-B5A3-5BE9060A4610Q28076304-3DE3600D-6C8D-405F-B0CB-AFD9E03D2971Q28076467-D6F20CE4-8D9C-4AFD-8474-C57CD24D9C3EQ28395836-7C730792-DDB9-4423-8E2E-D047E5FC8C5CQ28596809-D40A54F0-3F79-46A2-B761-27BB7B9AFFEEQ33383208-BA556E35-5F66-45CB-BBDB-04C3A7DA8E5BQ33391448-3CCC97BD-6B95-451F-903A-C661EC4EFB9FQ33395544-5FA07DFC-9CB2-409E-B1AD-64467A3F6368Q33400292-955FBA98-C00C-4BF3-A8C0-158A88485F67Q33403230-B4855528-C71E-4CFA-9294-AF6509240709Q33407183-F23ED337-EE13-4A29-8007-BD1849C3B205Q33417320-5F19D5D0-3CEB-44C3-A864-83EE6A540070Q33417537-2FC16720-084B-4276-BA2B-4FB3AE612FACQ33423381-196E1C1D-E928-4E7A-8298-A83290669E05Q33424869-D0041033-D13F-4D4A-8886-588E048661A4Q33434764-BBC7E100-AA6F-49B2-9B28-B08B1FDBEFB8Q33437893-72DF796E-2AB9-41F2-95AE-029114A80167Q33443519-D5745CE6-ED13-4FDF-A8F6-17DF77F38B00Q33554085-6D1132C0-E3E6-4016-BE76-33183E65BB30Q33723735-AD55A46D-638E-4C6E-B5DA-9AED486F4887Q33780751-13FB37A0-B397-4586-A611-BEC42ED2D65BQ33799729-488E97B0-36F1-4079-A2C2-6C31FBE43D6EQ33988305-8EB6680A-6E27-4DBC-A372-086021787DB5Q34000985-40239B29-C6DC-4518-A5A9-CACAB3218D90Q34026037-1569B93B-0799-44F7-90AB-4ABBC51B66CEQ34250859-EC27BE80-3BB6-4F72-B32D-6D7CF17AF72EQ34313435-828AF7D8-81A8-4A5B-ABBC-68B4E054FE5EQ34358063-6BD12471-8D52-4D2F-AA56-C8EBAE572E6FQ34363428-593C4630-276B-49EE-8185-E8F8BD79A337Q34512144-67E89AA8-D473-4603-942A-31057D87A808Q34565988-8624B3BC-21E6-45BB-B268-453836A94F1CQ34653756-F0FBE18D-8261-43CA-A62A-1FEA5D82D916Q34866341-26E2D652-B0A7-4E15-B8DF-7B3B6716B653Q35155464-130FB311-5297-456B-A6EE-F0115D85B16EQ35587164-03096039-64E6-48F9-9B0A-BC5F28B6ABEDQ35713556-EB79B599-7BF3-41D5-A2C0-D947DDF5FAD0
P2860
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@ast
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@en
type
label
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@ast
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@en
prefLabel
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@ast
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@en
P2093
P356
P1476
Phase III trial comparing supp ...... lapsed small-cell lung cancer.
@en
P2093
Branka Cuceviá
Gabor Juhasz
Graham A Ross
Graham C Dane
Hristo Tsekov
Mary E R O'Brien
Nicholas Thatcher
Theresa Crofts
Tudor-Eliade Ciuleanu
Yaroslav Shparyk
P304
P356
10.1200/JCO.2006.06.5821
P407
P577
2006-12-01T00:00:00Z